NCT04512261: TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases

NCT04512261
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have measurable central nervous system (CNS) metastases
Exclusions: Patients with an indication for immediate central nervous system (CNS)-directed therapy; Patients with leptomeningeal disease; Patients with prior therapy of tucatinib or an anti-PD-1 or anti-PD-L1/2 agent (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab)
https://ClinicalTrials.gov/show/NCT04512261

Comments are closed.

Up ↑